Biotech | August 25, 2021
Carbogen Amcis AG signs co-investment agreement
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
The foundation has been working closely with the Kidwai Memorial Institute of Oncology on several projects since 2001
It is the first branded generic alternative to Fostair 100/6 pMDI
BD worked with JCI to create a Gold Standard benchmarked safety program called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME)
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
The software enables real-time communication between patients, caregivers, physicians, and pharmacists and each cartridge in the device has a unique, traceable serial number registered to the patient
Shanghai Roche Pharmaceuticals and Shanghai KeChow Pharma, entered into a cooperation agreement to improve market access of Zelboraf in China.
Surgeries for the replacement of hip and knee joints have become common, the ones for the replacement of jaw joints and the use of 3D printed custom-made joints are new
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
Subscribe To Our Newsletter & Stay Updated
